Textbook of Clinical Management of Club Drugs and Novel Psychoactive Substances NEPTUNE Clinical Guidance
Book contents
- Textbook of Clinical Management of Club Drugs and Novel Psychoactive Substances
- Textbook of Clinical Management of Club Drugs and Novel Psychoactive Substances
- Copyright page
- Contents
- Acknowledgements
- Part I Introduction and Background
- Part II Drugs with Primarily Depressant Effects
- Chapter 3 Gamma-Hydroxybutyrate (GHB) and Gamma-Butyrolactone (GBL)
- Chapter 4 New Benzodiazepine Novel Psychoactive Substances
- Chapter 5 Synthetic Opioid Novel Psychoactive Substances (Fentanyl and Non-fentanyl)
- Chapter 6 Ketamine and Other Novel Psychoactive Substances with Dissociative Effects
- Chapter 7 Nitrous Oxide (N2O)
- Part III Drugs with Primarily Stimulant Effects
- Part IV Drugs with Primarily Hallucinogenic Effects
- Part V Synthetic Cannabinoid Receptor Agonists
- Part VI Concluding Remarks
- Index
- References
Chapter 5 - Synthetic Opioid Novel Psychoactive Substances (Fentanyl and Non-fentanyl)
from Part II - Drugs with Primarily Depressant Effects
Published online by Cambridge University Press: 06 October 2022
Book contents
- Textbook of Clinical Management of Club Drugs and Novel Psychoactive Substances
- Textbook of Clinical Management of Club Drugs and Novel Psychoactive Substances
- Copyright page
- Contents
- Acknowledgements
- Part I Introduction and Background
- Part II Drugs with Primarily Depressant Effects
- Chapter 3 Gamma-Hydroxybutyrate (GHB) and Gamma-Butyrolactone (GBL)
- Chapter 4 New Benzodiazepine Novel Psychoactive Substances
- Chapter 5 Synthetic Opioid Novel Psychoactive Substances (Fentanyl and Non-fentanyl)
- Chapter 6 Ketamine and Other Novel Psychoactive Substances with Dissociative Effects
- Chapter 7 Nitrous Oxide (N2O)
- Part III Drugs with Primarily Stimulant Effects
- Part IV Drugs with Primarily Hallucinogenic Effects
- Part V Synthetic Cannabinoid Receptor Agonists
- Part VI Concluding Remarks
- Index
- References
Summary
New synthetic opioids are an increasing risk for public health across the world. These drugs can be divided into two categories, pharmaceutical and non-pharmaceutical fentanyls, as well as non-fentanyl opioid novel psychoactive substances (NPS). These NPS are easily available on the Internet and are characterised by low price, purity, legality, and lack of detection in laboratory tests. However, most have not been approved or are not recommended for human use.
- Type
- Chapter
- Information
- Textbook of Clinical Management of Club Drugs and Novel Psychoactive SubstancesNEPTUNE Clinical Guidance, pp. 78 - 100Publisher: Cambridge University PressPrint publication year: 2022
References
Karila L, , Marillier M, , Chaumette B, , Billieux J, , Franchitto N, , Benyamina A., New synthetic opioids: part of a new addiction landscape. Neurosci Biobehav Rev 2019;106:133–140.Google Scholar
Stoicea, N, Costa A, , Periel L, , Uribe A, , Weaver T, , Bergese SD. Current perspectives on the opioid crisis in the US healthcare system: a comprehensive literature review. Medicine 2019;98(20):e15425. https://doi.org/10.1097/MD.0000000000015425Google Scholar
European School Survey Project on Alcohol and Other Drugs. Published 2015. Available at: www.espad.org/sites/espad.org/files/ESPAD_report_2015.pdf [last accessed 28 February 2022].Google Scholar
European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2019: Trends and Developments. Publications Office of the European Union, Luxembourg, 2019.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2019: Trends and Developments. Publications Office of the European Union, Luxembourg, 2019.Google Scholar
Pichini, S, Solimini, R, Berretta, P, Pacifici, R, Busardò, FP. Acute intoxications and fatalities from illicit fentanyl and analogues: an update. Ther Drug Monit 2018;40:38–51. https://doi.org/10.1097/FTD.0000000000000465CrossRefGoogle ScholarPubMed
Schifano F, , Chiappini S, , Corkery JM, , Guirguis A., Assessing the 2004–2018 fentanyl misusing issues reported to an international range of adverse reporting systems. Front Pharmacol 2019;10:46.Google Scholar
The United Nations Office on Drugs and Crime (UNODC). World Drug Report 2019 (United Nations publication, Sales No. E.19.XI.8). Available at: https://wdr.unodc.org/wdr2019/prelaunch/WDR19_Booklet_1_EXECUTIVE_SUMMARY.pdf; www.unodc.org/wdr2018/prelaunch/WDR18_Booklet_1_EXSUM.pdf [last accessed 28 February 2022].Google Scholar
Schifano F, , Chiappini S, , Corkery JM, , Guirguis A., Assessing the 2004–2018 fentanyl misusing issues reported to an international range of adverse reporting systems. Front Pharmacol 2019;10:46.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2019: Trends and Developments. Publications Office of the European Union, Luxembourg, 2019.Google Scholar
The United Nations Office on Drugs and Crime (UNODC). World Drug Report 2020 (United Nations publication, Sales No. E.20.XI.6).Google Scholar
United Nations Office on Drugs and Crime (UNODC). Fentanyl and its analogues – 50 years on. Global SMART Update, 2017.Google Scholar
Ayres, WA, Starsiak, MJ, Sokolay, P. The bogus drug: three methyl and alpha methyl fentanyl sold as ‘China White’. J Psychoactive Drugs 1981;13(1):91–93.CrossRefGoogle ScholarPubMed
Higashikawa, Y, Suzuki, S. Studies on 1-(2-phenethyl)-4-(N-propionylanilino) piperidine (fentanyl) and its related compounds. VI. Structure–analgesic activity relationship for fentanyl, methyl-substituted fentanyls and other analogues. Forensic Toxicol 2008;26(1):1–5. https://doi.org/10.1007/s11419-007-0039–1Google Scholar
Advisory Council on the Misuse of Drugs (ACMD). Misuse of Fentanyl and Fentanyl Analogues. January 2020.0Google Scholar
Lemmens, H. Pharmacokinetic-pharmacodynamic relationships for opioids in balanced anaesthesia. Clin Pharmacokinet 1995;29:231–242.Google Scholar
Janssen, PA. Potent, new analgesics, tailormade for different purposes. Acta Anaesthesiol Scand 1982;26(3):262–268.Google Scholar
Pichini S, , Zaami S, , Pacifici R, , Tagliabracci A, , Busardò FP. The challenge posed by new synthetic opioids: pharmacology and toxicology. Front Pharmacol 2019;10:563.Google Scholar
Pearson J, Poklis J, Poklis A, et al. Post-mortem toxicology findings of acetyl fentanyl, fentanyl, and morphine in heroin fatalities in Tampa, Florida. Acad Forensic Pathol 2015;5(4):676–689.CrossRefGoogle Scholar
Pompei, P, Micioni Di Bonaventura MV, Cifani C. The ‘legal highs’ of novel drugs of abuse. J Drug Abuse 2016;2:2.Google Scholar
Fairbairn, N, Coffin, PO, Walley, AY. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: challenges and innovations responding to a dynamic epidemic. Int J Drug Policy 2017;46:172–179. https://doi.org/10.1016/j.drugpo.2017.06.005Google Scholar
Armenian, P, Vo, KT, Barr-Walker, J, Lynch, KL. Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review. Neuropharmacology 2017;pii:S0028–3908(17)30484-7. https://doi.org/10.1016/jneuropharm.2017.10.016Google Scholar
Pérez-Mañá C, , Papaseit E, , Fonseca F, , Farré A, , Torrens M, , Farré M., Drug interactions with new synthetic opioids Front Pharmacol 2018 (online). https://doi.org/10.3389/fphar.2018.01145.Google Scholar
Labutin, AV, Temerdashev, AZ, Dukova, OA, et al. Identification of furanoylfentanil and its metabolites in human urine. J Environ Anal Toxicol 2017;7:3. https://doi.org/10.4172/2161-0525.1000456Google Scholar
Zawilska, JB. An expanding world of novel psychoactive substances: opioids. Front Psychiatry 2017;8:110. https://doi.org/10.3389/fpsyt.2017.00110Google Scholar
Pérez-Mañá C, , Papaseit E, , Fonseca F, , Farré A, , Torrens M, , Farré M., Drug interactions with new synthetic opioids Front Pharmacol 2018 (online). https://doi.org/10.3389/fphar.2018.01145.Google Scholar
Pérez-Mañá C, , Papaseit E, , Fonseca F, , Farré A, , Torrens M, , Farré M., Drug interactions with new synthetic opioids Front Pharmacol 2018 (online). https://doi.org/10.3389/fphar.2018.01145.Google Scholar
Daniulaityte, R, Juhascik, MP, Strayer, KE, et al. Overdose deaths related to fentanyl and its analogs – Ohio, January–February 2017. Morb Mortal Wkly Rep 2017;66:904–908. https://doi.org/10.15585/mmwr.mm6634a3Google Scholar
Rogers, JS, Rehrer, SJ, Hoot, NR. Acetylfentanyl: an emerging drug of abuse. J Emerg Med 2016;50(3):433–436. https://doi.org/10.1016/j.jemermed.2015.10.014Google Scholar
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Report on the Risk Assessment of Nphenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide (Furanylfentanyl) in the Framework of the Council Decision on New Psychoactive Substances. Lisbon, EMCDDA, 2017.Google Scholar
Rojkiewicz, M, Majchrzak, M, Celinski, R, Kus, P, Sajewicz, M. Identification and physicochemical characterization of 4-fluorobutyrfentanyl (1-((4-fluorophenyl)(1- phenethylpiperidin-4-yl)amino)butan-1-one, 4-FBF) in seized materials and postmortem biological samples. Drug Test Anal 2017;9:405–414.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Fentanyl drug profile. Available at: www.emcdda.europa.eu/publications/drug-profiles/fentanyl_en [last accessed 23 April 2022].Google Scholar
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report 2017: Trends and Developments. Luxembourg: Publications Office of the European Union, 2017.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2019: Trends and Developments. Publications Office of the European Union, Luxembourg, 2019.Google Scholar
Mounteney, J, Giraudon, I, Denissov, G, Griffiths, P. Fentanyls: are we missing the signs? Highly potent and on the rise in Europe. Int J Drug Pol 2015;26:626–631. https://doi.org/10.1016/j.drugpo.2015.04.003Google Scholar
Pichini S, Pacifici R, Marinelli E, Busardò FP. European drug users at risk from illicit fentanyls mix. Front Pharmacol 2017;31:785. https://doi.org/10.3389/fphar. 2017.00785Google Scholar
Pichini, S, Solimini, R, Berretta, P, Pacifici, R, Busardò, FP. Acute intoxications and fatalities from illicit fentanyl and analogues: an update. Ther Drug Monit 2018;40:38–51. https://10.1097/FTD.0000000000000465Google Scholar
European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2019: Trends and Developments. Publications Office of the European Union, Luxembourg, 2019.Google Scholar
Klar, SA, Brodkin, E, Gibson, E, et al. Notes from the field: furanyl-fentanyl overdose events caused by smoking contaminated crack cocaine – British Columbia, Canada, 15–18 July 2016. Morb Mortal Weekly Rep 2016;65(37):1015–1016. https://doi.org/10.15585/mmwr.mm6537a6CrossRefGoogle Scholar
Frank, RG, Pollack, HA. Addressing the fentanyl threat to public health. N Engl J Med 2017;376(7):605–607. https://doi.org/10.1056/NEJMp1615145Google Scholar
Arens, AM, van Wijk, XMR, Vo, KT, et al. Adverse effects from counterfeit alprazolam tablets. JAMA Intern Med 2016;176(10):1554–1555. https://doi.org/doi:10.1001/jamainternmed.2016.4306Google Scholar
Green, TC, Gilbert, M. Counterfeit medications and fentanyl. JAMA Inter Med 2016;176(10):1555–1557. https://doi.org/10.1001/jamai- nternmed.2016.4310Google Scholar
Stogner, JM. The potential threat of acetyl fentanyl: legal issues, contaminated heroin, and acetyl fentanyl ‘disguised’ as other opioids. Ann Emerg Med 2014;64(6):637–639. https://doi.org/10.1016/j. annemergmed.2014.07.017Google Scholar
Lozier, MJ, Boyd, M, Stanley, C, et al. Acetyl fentanyl, a novel fentanyl analog, causes overdose deaths in Rhode Island, March–May 2013. J Med Toxicol 2015;11:208–217. https://doi.org/10.1007/s13181-015-0477-9Google Scholar
Advisory Council on the Misuse of Drugs (ACMD). Misuse of Fentanyl and Fentanyl Analogues. January 2020.Google Scholar
Suzuki, J, El-Haddad, S. A review: fentanyl and non-pharmaceutical fentanyls. Drug Alcohol Depend 2016;171:107–116. https://doi.org/10.1016/j. drugalcdep. 2016.11.033Google Scholar
Stanley, TH. The fentanyl story. J Pain 2014;15:1215–1226. https://doi.org/10.1016/j. jpain.2014.08.010 10Google Scholar
Armenian, P, Olson, A, Anaya, A, et al. Fentanyl and a novel synthetic opioid U-47700 masquerading as street ‘Norco’ in Central California: a case report. Ann Emerg Med 2017;69:87–90.Google Scholar
Miller, JM, Stogner, JM, Miller, BL, Blough, S. Exploring synthetic heroin: accounts of acetyl fentanyl use from a sample of dually diagnosed drug offenders. Drug Alcohol Rev 2017;37(1):121–127. https://doi.org/10.1111/dar.12502Google Scholar
Amlani, A, McKee, G, Khamis, N, et al. Why the FUSS (Fentanyl Urine Screen Study)? A cross-sectional survey to characterize an emerging threat to people who use drugs in British Columbia, Canada. Harm Reduction J 2015;12:54. https://doi.org/10.1186/s12954-015-0088-4Google Scholar
Ciccarone, D, Ondocsin, J, Mars, S. Heroin uncertainties: exploring users’ perceptions of fentanyl-adulterated and -substituted heroin. Int J Drug Policy 2017;46:146–155.Google Scholar
Macmadu, A, Carroll, JJ, Hadland, SE, et al. Prevalence and correlates of fentanyl-contaminated heroin exposure among young adults who use prescription opioids non-medically. Addict Behav 2017;68:35–38. https://doi.org/10.1016/j.addbeh.2017.01.014Google Scholar
Prekupec MP, , Mansky PA, , Baumann MH., Misuse of novel synthetic opioids: a deadly new trend. J Addict Med 2017;11:256–265.Google Scholar
Gill, H, Kelly, E, Henderson, H. How the complex pharmacology of the fentanyls contributes to their lethality. Addiction 2019 (online). https://doi.org/10.1111/add.14614Google Scholar
McClain, DA, Hug, CC Jr. Intravenous fentanyl kinetics. Clin Pharmacol Ther 1980;28(1):106–114.Google Scholar
Siddiqi, S, Verney, C, Dargan, P, et al. Understanding the availability, prevalence of use, desired effects, acute toxicity and dependence potential of the novel opioid MT-45. Clin Toxicol 2015;53(1):54–59.Google Scholar
Gladden, RM, Martinez, P, Seth, P. Fentanyl law enforcement submissions and increases in synthetic opioid-involved overdose deaths – 27 states, 2013–2014. Morb Mortal Wkly Rep 2016;65:837–843.Google Scholar
Peterson, AB, Gladden, RM, Delcher, C, et al. Increases in fentanyl-related overdose deaths – Florida and Ohio, 2013–2015. Morb Mortal Wkly Rep 2016;65:844–849.Google Scholar
United Nations Office on Drugs and Crime Early Warning Advisory. Deaths associated with use of emerging synthetic opioids (News announcement). November 2016.Google Scholar
Advisory Council on the Misuse of Drugs (ACMD). Misuse of Fentanyl and Fentanyl Analogues. January 2020.Google Scholar
Gill, H, Kelly, E, Henderson, H. How the complex pharmacology of the fentanyls contributes to their lethality. Addiction 2019 (online). https://doi.org/10.1111/add.14614Google Scholar
Bowdle, TA. Adverse effects of opioid agonists and agonist-antagonists in anaesthesia. Drug Saf 1998;19:173–189.Google Scholar
Armenian, P, Vo, KT, Barr-Walker, J, Lynch, KL. Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review. Neuropharmacology 2017;134:121–132. https://doi.org/10.1016/j.neuropharm.2017.10.016Google Scholar
Prekupec, MP, Mansky, PA, Baumann, MH. Misuse of novel synthetic opioids: a deadly new trend. J Addict Med 2017;11:256–265. https://doi.org/10.1097/ ADM.0000000000000324Google Scholar
Ventura, L, Carvalho, F, Dinis-Oliveira, RJ. Opioids in the frame of new psychoactive substances network: a complex pharmacological and toxicological issue. Curr Mol Pharmacol 2018;11:97–108. https://doi.org/10.2174/ 1874467210666170704110146Google Scholar
Solimini, R, Pichini, S, Pacifici, R, Busardò, FP, Giorgetti, R. Pharmatoxicology of non-fentanyl derived new synthetic opioids. Front Pharmacol 2018;9:654. https://doi.org/10.3389/fphar.2018.00654Google Scholar
Kinshella, MW, Gauthier, T, Lysyshyn, M. Rigidity, dyskinesia and other atypical overdose presentations observed at a supervised injection site, Vancouver, Canada. Harm Reduct J 2018;15:64. https://doi.org/10.1186/s12954-018-0271-5Google Scholar
Mayer, S, Boyd, J, Collins, A, Kennedy, MC, Fairbairn, N, McNeil, R. Characterizing fentanyl-related overdoses and implications for overdose response: findings from a 64 rapid ethnographic study in Vancouver, Canada. Drug Alcohol Depend 2018;193:69–74. https://doi.org/10.1016/j.drugalcdep.2018.09.006.Google Scholar
Torralva, PR, Janowsky, A. Noradrenergic mechanisms in fentanyl-mediated rapid death explain failure of naloxone in the opioid crisis. J Pharmacol Exp Ther 2019;371 (2):453–475. https://doi.org/10.1124/jpet.119.258566Google Scholar
Burns, G, DeRienz, RT, Baker, DD, et al. Could chest wall rigidity be a factor in rapid death from illicit fentanyl abuse? Clin Toxicol 2016;54(5):420–423.Google Scholar
Armenian, P, Vo, KT, Barr-Walker, J, Lynch, KL. Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review. Neuropharmacology 2017;134:121–132. https://doi.org/10.1016/j.neuropharm.2017.10.016Google Scholar
Somerville, NJ, O’Donnell, J, Gladden, RM, et al. Characteristics of fentanyl overdose – Massachusetts, 2014–2016. Morb Mortal Wkly Rep 2017;66(14):382–386.Google Scholar
Prekupec, MP, Mansky, PA, Baumann, MH. Misuse of novel synthetic opioids: a deadly new trend. J Addict Med 2017;11:256–265. https://doi.org/10.1097/ ADM.0000000000000324Google Scholar
Ventura, L, Carvalho, F, Dinis-Oliveira, RJ. Opioids in the frame of new psychoactive substances network: a complex pharmacological and toxicological issue. Curr Mol Pharmacol 2018;11:97–108. https://doi.org/10.2174/ 1874467210666170704110146Google Scholar
Solimini, R, Pichini, S, Pacifici, R, Busardò, FP, Giorgetti, R. Pharmatoxicology of non-fentanyl derived new synthetic opioids. Front Pharmacol 2018;9:654. https://doi.org/10.3389/fphar.2018.00654Google Scholar
Cole, JB, Dunbar, JF, McIntire, SA, et al. Butyrfentanyl overdose resulting in diffuse alveolar hemorrhage. Pediatrics 2015;235(3). https://doi.org/10.1542/peds.2014-2878Google Scholar
Ruzycki, S, Yarema, M, Dunham, M, et al. Intranasal fentanyl intoxication leading to diffuse alveolar hemorrhage. J Med Toxicol 2016;12(1):185–188.Google Scholar
Kucuk, HO, Kucuk, U, Kolcu, Z, et al. Misuse of fentanyl transdermal patch mixed with acute coronary syndrome. Hum Exp Toxicol 2016;35(1):51–52.Google Scholar
Duru, UB, Pawar, G, Barash, JA, et al. An unusual amnestic syndrome associated with combined fentanyl and cocaine use. Ann Intern Med 2018 (online). https://doi.org/10.7326/L17-0575Google Scholar
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Cyclopropylfentanyl. EMCDDA–Europol Joint Report on a new psychoactive substance: N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl] cyclopropanecarboxamide (cyclopropylfentanyl). Available at: www.emcdda.europa.eu/system/files/publications/7926/20181014_TDAS18001ENN_PDF.pdf [last accessed 23 April 2022].Google Scholar
Pérez-Mañá C, , Papaseit E, Fonseca F, Farré A, Torrens M, Farré M. Drug interactions with new synthetic opioids. Front Pharmacol 2018 (online). https://doi.org/10.3389/fphar.2018.01145Google Scholar
Helander, A, Bäckberg, M, Signell, P, Beck, O. Intoxications involving acrylfentanyl and other novel designer fentanyls – results from the Swedish STRIDA project. Clin Toxicol 2017;55(6):589–599.Google Scholar
Pichini, S, Solimini, R, Berretta, P, et al. Acute intoxications and fatalities from illicit fentanyl and analogues: an update. Ther Drug Monit 2018;40(1):38–51. https://doi.org/10.1097/FTD.0000000000000465Google Scholar
Roxburgh, A, Burns, L, Drummer, OH, et al. Trends in fentanyl prescriptions and fentanyl-related mortality in Australia. Drug Alcohol Rev 2013;32(3):269–275.Google Scholar
Rodda, LN, Pilgrim, JL, Di Rago, M, et al. A cluster of fentanyl-laced heroin deaths in 2015 in Melbourne, Australia. Anal Toxicol 2017;41(4):318–324. https://doi.org/10.1093/jat/bkx013Google Scholar
Guerrieri, D, Roman, M, Thelander, G, Kronstrand, R. Acrylfentanyl: another new psychoactive drug with fatal consequences. Forensic Sci Int 2017;277:e21–e29. https://doi.org/10.1016/j.forsciint.2017.05.010CrossRefGoogle ScholarPubMed
Rudd, RA, Seth, P, David, F, et al. Increases in drug and opioid-involved overdose deaths: United States, 2010–2015. Morb Mortal Wkly Rep 2016;65:1445–1452.Google Scholar
Warner, M, Chen, LH, Makuc, DM, et al. Drug Poisoning Deaths in the United States, 1980–2008 (NCHS Data Brief, No. 81). Hyattsville, MD, National Center for Health Statistics, 2011. Available at www.cdc.gov/nchs/products/databriefs/db81.htm [last accessed 28 February 2022].Google Scholar
Chen, LH, Hedegaard, H, Warner, M. Drug-poisoning Deaths Involving Opioid Analgesics: United States, 1999–2011 (NCHS Data Brief, No. 166). Hyattsville, MD, National Center for Health Statistics, 2014. Available at: www.cdc.gov/nchs/products/databriefs/db166.htm [last accessed 28 February 2022].Google Scholar
Hedegaard, H, Chen, LH, Warner, M. Drug-poisoning Deaths Involving Heroin: United States, 2000–2013 (NCHS Data Brief, No. 190). Hyattsville, MD: National Center for Health Statistics, 2015. Available at: www.cdc.gov/nchs/products/databriefs/db190.htm [last accessed 28 February 2022].Google Scholar
National Center for Health Statistics. Public-use Data Files: Mortality Multiple Cause Files, 2015.Google Scholar
Centre for Disease Control and Prevention. Synthetic Opioid Data Excluding Methadone but Including Drugs Like Tramadol and Fentanyl.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Europol. Joint Report on a New Psychoactive Substance: 2-methoxy-N-phenyl-N-[1-(2-phenylethyl) piperidin-4-yl]acetamide (methoxyacetylfentanyl). Available at: www.emcdda.europa.eu/system/files/publications/7925/20181015_TDAS18002ENN_PDF.pdf [last accessed 28 February 2022].Google Scholar
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Europol. Joint Report on a New Psychoactive Substance: N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl] cyclopropanecarboxamide (cyclopropylfentanyl). Available at: www.emcdda.europa.eu/system/files/publications/7926/20181014_TDAS18001ENN_PDF.pdf [last accessed 28 February 2022].Google Scholar
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Prevention of Drug-related Deaths. Available at: www.emcdda.europa.eu/publications/topic-overviews/prevention-drug-related-deaths [last accessed 28 February 2022].Google Scholar
Drummer OH., Fatalities caused by novel opioids: a review. Forensic Sci Res 2019;4(2):95–110. https://doi.org/10.1080/20961790.2018.1460063Google Scholar
Lovrecic B, , Lovrecic M, , Gabrovec B, , et al. Non-medical use of novel synthetic opioids: a new challenge to public health. Int. J. Environ. Res. Public Health 2019;16:177. https://doi.org/10.3390/ijerph16020177Google Scholar
Drummer OH., Fatalities caused by novel opioids: a review. Forensic Sci Res 2019;4(2):95–110. https://doi.org/10.1080/20961790.2018.1460063Google Scholar
Lovrecic B, , Lovrecic M, , Gabrovec B, , et al. Non-medical use of novel synthetic opioids: a new challenge to public health. Int J Environ Res Public Health 2019;16:177. https://doi.org/10.3390/ijerph16020177Google Scholar
Drummer OH., Fatalities caused by novel opioids: a review. Forensic Sci Res 2019;4(2):95–110. https://doi.org/10.1080/20961790.2018.1460063Google Scholar
Lovrecic B, , Lovrecic M, , Gabrovec B, , et al. Non-medical use of novel synthetic opioids: a new challenge to public health. Int J Environ Res Public Health 2019;16:177. https://doi.org/10.3390/ijerph16020177Google Scholar
Hull, MJ, Juhascik, M, Mazur, F, et al. Fatalities associated with fentanyl and co-administered cocaine or opiates. J Forensic Sci 2007;52:1383–1388.Google Scholar
Drummer OH., Fatalities caused by novel opioids: a review. Forensic Sci Res 2019;4(2):95–110. https://doi.org/10.1080/20961790.2018.1460063Google Scholar
Ojanpera, I, Gergov, M, Liiv, M, et al. An epidemic of fatal 3-methylfentanyl poisoning in Estonia. Int J Legal Med 2008;122:395–400.Google Scholar
Marinetti, LJ, Ehlers, BJ. A series of forensic toxicology and drug seizure cases involving illicit fentanyl alone and in combination with heroin, cocaine or heroin and cocaine. J Anal Toxicol 2014;38:592–598.Google Scholar
National Center for Biotechnology Information. PubChem Compound Summary for CID 62156, Carfentanil. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/Carfentanil [last accessed1March2022].Google Scholar
Lovrecic B, , Lovrecic M, , Gabrovec B, , et al. Non-medical use of novel synthetic opioids: a new challenge to public health. Int J Environ Res Public Health 2019;16:177. https://doi.org/10.3390/ijerph16020177Google Scholar
Bäckberg, M, Beck, O, Jönsson, K-H, Helander, A. Opioid intoxications involving butyrfentanyl, 4-fluorobutyrfentanyl, and fentanyl from the Swedish STRIDA project. Clin Toxicol 2015;53(7):609–617. https://doi.org/10.3109/15563650.2015.1054505Google Scholar
McIntyre, IM, Anderson, DT. Post-mortem fentanyl concentrations: a review. J Forensic Res 2012;3:157.Google Scholar
Latimer, J, Ling, S, Flaherty, I, et al. Risk of fentanyl overdose among clients of the Sydney Medically Supervised Injecting Centre. Int J Drug Policy 2016;37:111–114.Google Scholar
Darke, S, Duflou, J. The toxicology of heroin-related death: estimating survival times. Addiction 2016;111(9):1607–1613. https://doi.org/10.1111/ add.13429Google Scholar
Kim HK, , Connors NJ, , Mazer-Amirshahi ME., The role of take-home naloxone in the epidemic of opioid overdose involving illicitly manufactured fentanyl and its analogs. Expert Opin Drug Saf 2019(online). https://doi.org/10.1080/14740338.2019.1613372Google Scholar
Henderson, GL. Fentanyl-related deaths: demographics, circumstances, and toxicology of 112 cases. J Forensic Sci 1991;36(2):422–433.Google Scholar
Woodall, KL, Martin, TL, McLellan, BA. Oral abuse of fentanyl patches (Duragesic®): seven case reports. J Forensic Sci 2008;53(1):222–225. https://doi.org/10.1111/j.1556-4029.2007.00597.xGoogle Scholar
O’Donnell, JK, Halpin, J, Mattson, CL, et al. Deaths involving fentanyl, fentanyl analogs, and u-47700 – 10 states, July–December 2016. Morb Mortal Wkly Rep 2017;66(43):1197–1202. https://doi.org/10.15585/mmwr.mm6643e1Google Scholar
Gomes, T, Juurlink, DN, Mamdani, MM, et al. Prevalence and characteristics of opioid-related deaths involving alcohol in Ontario, Canada. Drug Alcohol Depend 2017;179:416–423.Google Scholar
Pérez-Mañá, C, Papaseit, E, Fonseca, F, Farré, A, Torrens, M, Farré, M. Drug interactions with new synthetic opioids. Front Pharmacol 2018 (online). | https://doi.org/10.3389/fphar.2018.01145Google Scholar
Pérez-Mañá C, , Papaseit E, , Fonseca F, , Farré A, , Torrens M, , Farré M., Drug interactions with new synthetic opioids. Front Pharmacol 2018 (online). https://doi.org/10.3389/fphar.2018.01145Google Scholar
Atkinson, TJ, Fudin, J. Interactions between pain medications and illicit street drugs. Pract Pain Manag 2014;7:1–4.Google Scholar
Mozayani, A, Raymon, LP. Handbook of Drug Interactions. New Jersey, NJ, Humana Press Inc., 2004. https://doi.org/10.1007/978-1-59259-654-6Google Scholar
Pérez-Mañá C, , Papaseit E, , Fonseca F, , Farré A, , Torrens M, , Farré M., Drug interactions with new synthetic opioids. Front Pharmacol 2018 (online). https://doi.org/10.3389/fphar.2018.01145Google Scholar
Rickli, A, Liakoni, E, Hoener, MC, Liechti, ME. Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome. Br J Pharmacol 2018;175:532–543. https://doi.org/10.1111/bph.14105Google Scholar
Greenier, E, Lukyanova, V, Reede, L. Serotonin syndrome: fentanyl and selective serotonin reuptake inhibitor interactions. AANA J 2014;82(5):340–345.Google Scholar
National Institute for Health and Care Excellence. Fentanyl interactions. Available at: https://bnf.nice.org.uk/interaction/fentanyl-2.html?msclkid=fc39a64bc2f311ecb6896b20054e84be [last accessed 23 April 2022].Google Scholar
World Health Organization Expert Committee on Drug Dependence, thirty-ninth report. Geneva, WHO, 2018 (WHO Technical Report Series, No. 1009). License: CC BY-NC-SA 3.0 IGO.Google Scholar
Available at: www.unodc.org/documents/commissions/CND/Drug_Resolutions/2010-2019/2012/CND_Res-55-7.pdf; www.unodc.org/docs/treatment/overdose.pdf; https://sustainabledevelopment.un.org/sdg3; www.unodc.org/documents/brussels/News/2017.11_GERRA_S-O-S_initiative_Brochure_13.pdf [last accessed 1 March 2022.Google Scholar
World Health Organization. Community Management of Opioid Overdose, 2014. Available at: https://apps.who.int/iris/bitstream/handle/10665/137462/9789241548816_eng.pdf;jsessionid=F58F5BF19670B076BDF8B483B062C22F?sequence=1 [last accessed 1 March 2022].Google Scholar
Strang, J, McDonald, R. Preventing Opioid Overdose Deaths with Take-Home Naloxone. Publications Office of the European Union, Luxembourg. 2016. Available at:
www.emcdda.europa.eu/system/files/publications/2089/TDXD15020ENN.pdf [last accessed 1 March 2022].Google Scholar
European Monitoring Centre for Drugs and Drug Addiction. Take-Home Naloxone. Available at: www.emcdda.europa.eu/publications/topic-overviews/take-home-naloxone_en [last accessed 1 March 2022].Google Scholar
Advisory Council on the Misuse of Drugs. Misuse of Fentanyl and Fentanyl Analogues 2020. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/855893/ACMD_Report_-_Misuse_of_fentanyl_and_fentanyl_analogues.pdf [last accessed 1 March 2022].Google Scholar
World Health Organization. Community Management of Opioid Overdose Guideline, 2014. Available at: www.who.int/publications/i/item/9789241548816 [last accessed 23 April 2022].Google Scholar
Advisory Council on the Misuse of Drugs. Misuse of Fentanyl and Fentanyl Analogues. January 2020.Google Scholar
Mayer, S, Boyd, J, Collins, A, Kennedy, MC, Fairbairn, N, McNeil, R. Characterizing fentanyl-related overdoses and implications for overdose response: findings from a 64 rapid ethnographic study in Vancouver, Canada. Drug Alcohol Depend 2018;193:69–74. https://doi.org/10.1016/j.drugalcdep.2018.09.006.Google Scholar
NPIS, TOXBASE. www.toxbase.orgGoogle Scholar
Advisory Council on the Misuse of Drugs. Misuse of Fentanyl and Fentanyl Analogues. January 2020.Google Scholar
Lynn, RR, Galinkin, JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf 2018;9(1):63–88. https://doi.org/10.1177/2042098617744161Google Scholar
Advisory Council on the Misuse of Drugs. Misuse of Fentanyl and Fentanyl Analogues. January 2020.Google Scholar
Strang, J, McDonald, R (eds). Preventing Opioid Overdose Deaths with Take-Home Naloxone. Luxembourg, EMCDDA, 2016. Available at: www.emcdda.europa.eu/system/files/publications/2089/TDXD15020ENN.pdf [last accessed 23 April 2022].Google Scholar
Advisory Council on the Misuse of Drugs. Misuse of Fentanyl and Fentanyl Analogues. January 2020.Google Scholar
Moss RB, , Carlo DJ. Higher doses of naloxone are needed in the synthetic opioid era. Subst Abuse Treat Prev Policy 2019;14:6. https://doi.org/10.1186/s13011-019-0195-4Google Scholar
Lucyk, SN, Nelson, LS. Novel synthetic opioids: an opioid epidemic within an opioid epidemic. Ann Emerg Med 2017;69(1):91–93. https://doi.org/10.1016/j.annemergmed.2016.08.445Google Scholar
Ramos-Matos, C, López-Ojeda W. China White: clinical insights of an evolving designer underground drug. Universal J Clin Med 2015;3(1):6–9. https://doi.org/10.13189/ujcm.2015.030102Google Scholar
Neale, J, Strang, J. Naloxone – does over-antagonism matter? Evidence of iatrogenic harm after emergency treatment of heroin/opioid overdose. Addiction 2015;110(10):1644–1652. https://doi.org/10.1111/add.13027Google Scholar
Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence (2009). Available at: www.who.int/publications/i/item/9789241547543?msclkid=6d2b2cadc2f511ec84abaff20e8ad971; WHO: Community management of opioid overdose 2014. Available at: https://apps.who.int/iris/bitstream/handle/10665/137462/9789241548816_eng.pdf [last accessed 23 April 2022].Google Scholar
Strang J, McDonald R (eds). Preventing Opioid Overdose Deaths with Take-Home Naloxone. EMCDDA, 2016. Available at: www.emcdda.europa.eu/system/files/publications/2089/TDXD15020ENN.pdf [last accessed 23 April 2022].Google Scholar
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Take-Home Naloxone. Available at: www.emcdda.europa.eu/publications/topic-overviews/take-home-naloxone_en [last accessed 1 March 2022].Google Scholar
Strang, J, McDonald, R, Campbell, G, et al. Take-home naloxone for the emergency interim management of opioid overdose: the public health application of an emergency medicine. Drugs 2019;79:1395–1418. https://doi.org/10.1007/s40265-019-01154-5Google Scholar
Kim HK, Connors NJ, Mazer-Amirshahi ME. The role of take-home naloxone in the epidemic of opioid overdose involving illicitly manufactured fentanyl and its analogs. Expert Opin Drug Saf 2019 (online). https://doi.org/10.1080/14740338.2019.1613372Google Scholar
Schumann, H, Erickson, T, Thompson, TM, et al. Fentanyl epidemic in Chicago, Illinois and surrounding Cook County. Clin Toxicol (Phila) 2008;46:501–506.Google Scholar
Peipera NC, Duhart Clarke S, , Vincent LB, , Ciccarone D, , Krala AH, , Zibbella JE. Fentanyl test strips as an opioid overdose prevention strategy: findings from a syringe services program in the Southeastern United States. Int J Drug Policy 2019;63:122–128.Google Scholar
Goldman, JE, Waye, KM, Periera, KA, et al. Perspectives on rapid fentanyl test strips as a harm reduction practice among young adults who use drugs: a qualitative study. Harm Reduct J 2019;16:3. https://doi.org/10.1186/s12954-018-0276-0Google Scholar
Green, TC, Park, Nyeong J et al., MI An assessment of the limits of detection, sensitivity and specificity of three devices for public health-based drug checking of fentanyl in street-acquired samples. Int J Drug Policy 2020;77:102661.Google Scholar
Willman, MW, Liss, DB, Schwarz, ES, et al. Do heroin overdose patients require observation after receiving naloxone? Clin Toxicol 2017;55(2):81–87.Google Scholar
Cicero, TJ, Ellis, MS, Kasper, ZA. Increases in self-reported fentanyl use among a population entering drug treatment: the need for systematic surveillance of illicitly manufactured opioids. Drug Alcohol Depend 2017;177:101–103. https://doi.org/10.1016/j.drugalcdep.2017.04.004Google Scholar
European Monitoring Centre for Drugs and Drug Addiction. Estonia, Country Drug Report 2017. Luxembourg, Publications Office of the European Union, 2017.Google Scholar
Allan, J, Herridge, N, Griffiths, P, et al. Illicit fentanyl use in rural Australia – an exploratory study. J Alcohol Drug Depend 2015;3:196. https://doi.org/10.4172/23296488.1000196Google Scholar
Gecici, O, Gokmen, Z, Nebioglu, M. Fentanyl dependence caused by the non-medical use: a case report. Klinik Psikofarmakoloji Bülteni-Bull Clin Psychopharmacol 2010;20(3):255–257. https://doi.org/10.1080/10177833.2010.11790668Google Scholar
Ossipov, MH, Lai, J, King, T, et al. Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Biopolymers 2005;80(2–3):319–324.Google Scholar
Benyamin, R, Trescot, AM, Datta, S, et al. Opioid complications and side effects. Pain Physician 2008;11(2 Suppl.):S105–S120.Google Scholar
Ballantyne, JC. ‘Safe and effective when used as directed’: the case of chronic use of opioid analgesics. J Med Toxicol 2012;8(4):417–423.Google Scholar
Solomon, DH, Rassen, JA, Glynn, RJ, et al. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med 2010;170(22):1979–1986.Google Scholar
Firestone, M, Goldman, B, Fischer, B. Fentanyl use among street drug users in Toronto, Canada: behavioural dynamics and public health implications. Int J Drug Policy 2009;20(1):90–92. https://doi.org/10.1016/j.drugpo.2008.02.016Google Scholar
United Nations Office on Drugs and Crime (UNODC). World Drug Report 2017. Vienna, UNODC, 2017.Google Scholar
Advisory Council on the Misuse of Drugs (ACMD). Misuse of Fentanyl and Fentanyl Analogues. January 2020.Google Scholar
Solimini, R, Pichini, S, Pacifici, R, Busardò, FP, Giorgetti, R. Pharmatoxicology of non-fentanyl derived new synthetic opioids. Front Pharmacol 2018;9:654. https://doi.org/10.3389/fphar.2018.00654Google Scholar
Pérez-Mañá C, , Papaseit E, Fonseca F, Farré, Torrens M, Farré M. Drug interactions with new synthetic opioids. Front Pharmacol 2018 (online). https://doi.org/10.3389/fphar.2018.01145Google Scholar
Pérez-Mañá C, , Papaseit E, Fonseca F, Farré, Torrens M, Farré M. Drug interactions with new synthetic opioids. Front Pharmacol 2018 (online). https://doi.org/10.3389/fphar.2018.01145Google Scholar
Karinen, R, Tuv, SS, Rogde, S, et al. Lethal poisonings with AH-7921 in combination with other substances. Forensic Sci Int 2014;244:e21–e24.Google Scholar
Hayers, AG, Tyers, MB. Determination of receptors that mediate opiate side effects in the mouse. Br J Pharmacol 1983;79:731–736. https://doi.org/10.1111/ j.1476-5381.1983.tb10011.xGoogle Scholar
Ciccarone, D. Fentanyl in the US heroin supply: a rapidly changing risk environment. Int J Drug Policy 2017;46:107–111. https://doi.org/10.1016/j.drugpo.2017.06.010Google Scholar
Lovrecic B, , Lovrecic M, , Gabrovec B, et al. Non-medical use of novel synthetic opioids: a new challenge to public health. Int J Environ Res Public Health 2019;16:177. https://doi.org/10.3390/ijerph16020177Google Scholar
Cheney, BV, Szmuszkovicz, J, Lahti, RA, Zichi, DA. Factors affecting binding of trans-N-[2-(methylamino) cyclohexyl]benzamides at the primary morphine receptor. J Med Chem 1985;28:1853–1864.Google Scholar
Harper, NJ, Veitch, GB, Wibberley, DG. 1-(3,4-dichlorobenzamidomethyl)cyclohexyldimethylamine and related compounds as potential analgesics. J Med Chem 1974;17:1188–1193.Google Scholar
Papsun, D, Krywanczyk, A, Vose, JC, et al. Analysis of MT-45, a novel synthetic opioid, in human whole blood by LC–MS-MS and its identification in a drug-related death. J Anal Toxicol 2016;40(4):313–317. https://doi.org/10.1093/jat/bkw012Google Scholar
Helander, A, Bäckberg, M, Beck, O. MT-45, a new psychoactive substance associated with hearing loss and unconsciousness. Clin Toxicol 2014;52(8):901–904.Google Scholar
Katselou, M, Papoutsis, I, Nikolaou, P, Spiliopoulou, C, Athanaselis, S. AH-7921: the list of new psychoactive opioids is expanded. Forensic Toxicol 2015;33(2):195–201.Google Scholar
Coppola, M, Mondola, R. AH-7921: from potential analgesic medicine to recreational drug. Int J High Risk Behav Addict 2017;6(2):e22593. https://doi.org/10.5812/ijhrba.22593Google Scholar
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Technical report on 3,4-dichloro-N-{[1- (dimethylamino)cyclohexyl]methyl}benzamide (AH-7921). Lisbon, EMCDDA, April 2014.Google Scholar
Tabarra I, , Soares S, , Rosado T, et al. Novel synthetic opioids – toxicological aspects and analysis. Forensic Sci Res 2019;4(2):111–140. https://doi.org/10.1080/20961790.2019.1588933Google Scholar
European Monitoring Centre for Drugs and Drug Addiction. EMCDDA–Europol Joint Report on a New Psychoactive Substance: AH-7921. Luxembourg, Publications Office of the European Union, 2016. Available at: www.emcdda.europa.eu/publications/joint-report/AH-7921_en [last accessed 23 April 2022].Google Scholar
Uchiyama, N, Matsuda, S, Kawamura, M, et al. Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative a-PVT and an opioid receptor agonist AH-7921 identified in illegal products. Forensic Toxicol 2013;31:223–240.Google Scholar
Prekupec, MP, Mansky, PA, Baumann, MH. Misuse of novel synthetic opioids: a deadly new trend. J Addict Med 2017;11(4):256–265. https://doi.org/10.1097/ADM.0000000000000324Google Scholar
Uchiyama, N, Matsuda, S, Kawamura, M, et al. Identification of two new-type designer drugs, piperazine derivative MT-45 (I-C6) and synthetic peptide noopept (GVS-111), with synthetic cannabinoid A-834735, cathinone derivative 4-methoxy-alpha-PVP, and phenethylamine derivative 4-methylbuphedrine from illegal products. Forensic Toxicol 2014;32:9–18.Google Scholar
Kjellgren, A, Jacobsson, K, Soussan, C. The quest for well-being and pleasure: experiences of the novel synthetic opioids AH-7921 and MT-45, as reported by anonymous users online. J Addict Res Ther 2016;7(287):2.Google Scholar
Elliott, S, Brandt, S, Smith, C. The first reported fatality associated with the synthetic opioid 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-Nmethylbenzamide (U-47700) and implications for forensic analysis. Drug Test Anal 16-0092–R1. https://doi.org/10.1002/dta.1984Google Scholar
Kjellgren, A, Jacobsson, K, Soussan, C. The quest for well-being and pleasure: experiences of the novel synthetic opioids AH-7921 and MT-45, as reported by anonymous users online. J Addict Res Ther 2016;7(287):2.Google Scholar
Soussan, C, Kjellgren, A. The users of novel psychoactive substances: online survey about their characteristics, attitudes and motivations. Int J Drug Policy 2016;32:77–84.Google Scholar
Tabarra I, , Soares S, , Rosado T, et al. Novel synthetic opioids – toxicological aspects and analysis Forensic Sci Res 2019;4(2):111–140. https://doi.org/10.1080/20961790.2019.1588933Google Scholar
Katselou, M, Papoutsis, I, Nikolaou, P, et al. AH-7921: the list of new psychoactive opioids is expanded. Forensic Toxicol 2015;33:195–201. https://doi.org/10.1007/s11419-015-0271-zGoogle Scholar
Kjellgren, A, Jacobsson, K, Soussan, C. The quest for well-being and pleasure: experiences of the novel synthetic opioids AH-7921 and MT-45, as reported by anonymous users online. J Addict Res Ther 2016;7:287. https://doi.org/10.4172/2155-6105.1000287Google Scholar
Kjellgren, A, Jacobsson, K, Soussan, C. The quest for well-being and pleasure: experiences of the novel synthetic opioids AH-7921 and MT-45, as reported by anonymous users online. J Addict Res Ther 2016;7:287. https://doi.org/10.4172/2155-6105.1000287Google Scholar
Mohr, ALA, Friscia, M, Papsun, D, et al. Analysis of novel synthetic opioids U-47700, U-50488 and furanyl fentanyl by LC–MS/MS in post-mortem casework. J Anal Toxicol 2016;40:709–717. https://doi.org/10.1093/jat/bkw086Google Scholar
Elliott, SP, Brandt, SD, Smith, C. The first reported fatality associated with the synthetic opioid 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-Nmethylbenzamide (U-47700) and implications for forensic analysis. Drug Test Anal 2016;8:875–879. https://doi.org/10.1002/dta.1984Google Scholar
Kronstrand, R, Thelander, G, Lindstedt, D, Roman, M, Kugelberg, FC. Fatal intoxications associated with the designer opioid AH-7921. J Anal Toxicol 2014;38(8):599–604.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Technical report on 3,4-dichloro-N-{[1- (dimethylamino)cyclohexyl]methyl}benzamide (AH-7921). Lisbon, EMCDDA, April 2014.Google Scholar
Hayes, AG, Tyers, MB. Determination of receptors that mediate opiate side effects in the mouse. Br J Pharmacol ;79:731–736.Google Scholar
Elliott S, Brandt S, Smith C. The first reported fatality associated with the synthetic opioid 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-Nmethylbenzamide (U-47700) and implications for forensic analysis. Drug Test Anal 16- 0092-R1. https://doi.org/10.1002/dta.1984Google Scholar
Coppola, M, Mondola, R. AH-7921: from potential analgesic medicine to recreational drug. Int J High Risk Behav Addict 2017;6(2):e22593. https://doi.org/10.5812/ijhrba.22593Google Scholar
Tabarra I, , Soares S, , Rosado T, et al. Novel synthetic opioids – toxicological aspects and analysis. Forensic Sci Res 2019;4(2):111–140. https://doi.org/10.1080/20961790.2019.1588933Google Scholar
Hayes, AG, Tyers, MB. Determination of receptors that mediate opiate side effects in the mouse. Br J Pharmacol 1983;79:731–736.Google Scholar
Coppola, M, Mondola R. AH-7921: a new synthetic opioid of abuse. Drug Alcohol Rev 2015;34:109–110.Google Scholar
Coppola, M, Mondola R. MT-45: a new, dangerous legal high. J Opioid Management 2014;10:301–302.Google Scholar
Nakamura, H, Shimizu, M. Comparative study of 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine and its enantiomorphs on analgesic and other pharmacological activities in experimental animals. Arch Int Pharmacodyn Thér 1976;221:105–121.Google Scholar
Armenian, P, Vo, KT, Barr-Walker, J, Lynch, KL. Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review. Neuropharmacology 2017;134:121–132. https://doi.org/10.1016/j.neuropharm.2017.10.016Google Scholar
Prekupec, MP, Mansky, PA, Baumann, MH. Misuse of novel synthetic opioids: a deadly new trend. J Addict Med 2017;11:256–265. https://doi.org/10.1097/ ADM.0000000000000324Google Scholar
Ventura, L, Carvalho, F, Dinis-Oliveira, RJ. Opioids in the frame of new psychoactive substances network: a complex pharmacological and toxicological issue. Curr Mol Pharmacol 2018;11:97–108. https://doi.org/10.2174/ 1874467210666170704110146Google Scholar
Solimini, R, Pichini, S, Pacifici, R, Busardò, FP, Giorgetti, R. Pharmatoxicology of non-fentanyl derived new synthetic opioids. Front Pharmacol 2018;9:654. https://doi.org/10.3389/fphar.2018.00654Google Scholar
Helander, A, Bradley, M, Hasselblad, A, et al. Acute skin and hair symptoms followed by severe, delayed eye complications in subjects using the synthetic opioid MT-45. Br J Dermatol 2017;176:1021–1027.Google Scholar
Tabarra I, , Soares S, , Rosado T, et al. Novel synthetic opioids – toxicological aspects and analysis. Forensic Sci Res 2019;4(2):111–140. https://doi.org/10.1080/20961790.2019.1588933Google Scholar
Vorce, SP, Knittel, JL, Holler, JM, et al. A fatality involving AH-7921. J Analyt Toxicol 2014;38:226–230. https://doi.org/10.1093/jat/bku011Google Scholar
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Drugs in Focus 2011.Google Scholar
Advisory Council on the Misuse of Drugs (ACMD). ACMD’s Recommendation on the Synthetic Opiate AH-7921. London, ACMD, 2014.Google Scholar
Elliott, S, Evans, J. A 3-year review of new psychoactive substances in casework. Forensic Sci Int 2014;243:55–60. https://doi.org/10.1016/j.forsciint.2014.04.017Google Scholar
Soh, YNA, Elliott, S. An investigation of the stability of emerging new psychoactive substances. Drug Test Anal 2014;6(7–8):696–704. https://doi.org/10.1002/dta.1576Google Scholar
Kronstrand, R, Thelander, G, Lindstedt, D, et al. Fatal intoxications associated with the designer opioid AH-7921. J Anal Toxicol 2014;38:599–604. https://doi.org/10.1093/jat/bku057Google Scholar
Fels H, , Lottner-Nau S, , Sax T, , Roider G, , Graw M, . Postmortem concentrations of the synthetic opioid U-47700 in 26 fatalities associated with the drug. Forensic Sci Int 2019;301:e20–e28. https://doi.org/10.1016/j.forsciint.2019.04.010Google Scholar
Kriikku P, Pelander A, Rasanen I, Ojanperä I. Toxic lifespan of the synthetic opioid U-47,700 in Finland verified by re-analysis of UPLC-TOF-MS data. Forensic Sci Int 2019;300:85–88. https://doi.org/10.1016/j.forsciint.2019.04.030Google Scholar
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Report on the Risk Assessment of MT-45 in the Framework of the Council Decision on New Psychoactive Substances. Luxembourg, Publications Office of the European Union, 2015. Available at: www.emcdda.europa.eu/system/files/publications/1865/TDAK14006ENN.pdf [last accessed 23 April 2022].Google Scholar
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EMCDDA–Europol Joint Report on a New Psychoactive Substance: 1-cyclohexyl-4-(1,2- diphenylethyl)piperazine (‘MT-45’). Luxembourg, Publications Office of the European Union, 2014. Available at: www.emcdda.europa.eu/publications/joint-reports/MT-45_en [last accessed 23 April 2022].Google Scholar
Ruan, X, Chiravuri, S, Kaye, AD. Comparing fatal cases involving U-47700. Forensic Sci Med Pathol 2016;12:369–371.Google Scholar
Jones, MJ, Hernandez, BS, Janis, GC, et al. A case of U-47700 overdose with laboratory confirmation and metabolite identification. Clin Toxicol (Phila) 2017;55:55–59.Google Scholar
Coopman, V, Blanckaert, P, Van Parys, G, Van Calenbergh, S, Cordonnier, J. A case of acute intoxication due to combined use of fentanyl and 3,4-dichloro-N-[2-(dimethylamino) cyclohexyl]-N-methylbenzamide (U-47700). Forensic Sci Int 2016;266:68–72. https://doi.org/10.1016/j.forsciint.2016.05.001Google Scholar
Papsun, D, Krywanczyk, A, Vose, JC, Bundock, EA, Logan, BK. Analysis of MT-45, a novel synthetic opioid, in human whole blood by LC–MS–MS and its identification in a drug-related death. J Anal Toxicol 2016;40:313–317. https://doi.org/10.1093/jat/bkw012Google Scholar
Lucyk, SN, Nelson, LS. Novel synthetic opioids: an opioid epidemic within an opioid epidemic. Ann Emerg Med 2017;69:91–93. https://doi.org/10.1016/j.annemergmed.2016.08.445Google Scholar
Armenian, P, Olson, A, Anaya, A, Kurtz, A, Ruegner, R, Gerona, RR. Fentanyl and a novel synthetic opioid U-47700 masquerading as street ‘Norco’ in Central California: a case report. Ann Emerg Med 2017;69:87–90. https://doi.org/10.1016/j.annemergme d.2016.06.014Google Scholar
Brittain, RT, Kellett, DN, Neat, ML, et al. Anti-nociceptive effects in N-substituted cyclohexylmethylbenzamides. Br J Pharmacol 1973;49:158–159.Google Scholar
Tabarra I, , Soares S, , Rosado T, et al. Novel synthetic opioids – toxicological aspects and analysis. Forensic Sci Res 2019;4(2):111–140. https://doi.org/10.1080/20961790.2019.1588933Google Scholar